#Sweden #Gothenburg #Zinzino #Faun Pharma

Zinzino AB's February 2025 Revenue Report

Zinzino AB has unveiled its preliminary sales report for February 2025, highlighting an impressive growth trajectory. With a staggering 56% increase in revenue compared to the same month last year, the company’s sales reached a commendable SEK 212.7 million, up from SEK 136.4 million. This marks a significant achievement for the company, especially as it continues to expand its presence in various markets.

The overall performance in February reflects a thriving business environment for Zinzino, as the group revenue surged by 48% to total SEK 216.9 million, which is up from SEK 146.1 million a year prior. Analysing the accumulated revenue for the first two months of 2025, the figures reveal a robust increase of 53%, amounting to SEK 450.8 million, compared to SEK 295.0 million from the previous year.

Regional Breakdown

The revenue growth is distributed across several key regions, showcasing varying degrees of success. Here is a detailed examination of the regional performance:

• - The Nordics: Registered a revenue of SEK 24.8 million, reflecting an 11% increase year-on-year. This region, which includes Denmark, Finland, Iceland, Norway, and Sweden, has contributed notably to the overall figures.
• - Central Europe: This region saw a striking 58% increase, recording SEK 58.1 million compared to last year’s figures. Countries like Austria, Germany, and Switzerland have shown strong demand.
• - East Europe: A minor decrease of 4% led to revenues of SEK 29 million. Despite this, the region has maintained steady performance with a slight increase accumulated year-to-date.
• - South West Europe: Experiencing a 65% increase to SEK 37.9 million, markets in this region, including Spain and Italy, have significantly bolstered sales.
• - North America: Here, Zinzino has recorded phenomenal growth of 181% with revenues touching SEK 32.6 million. The U.S., Canada, and Mexico are key contributors, reflecting a burgeoning acceptance of Zinzino products.
• - Asia-Pacific: This region has proven to be a powerhouse with a staggering 485% growth, reporting SEK 19.9 million this February. Countries such as Australia, India, and Singapore show robust market penetration.
• - Africa: Lastly, revenue increased by 36% reaching SEK 1.5 million. While modest, this growth reflects emerging market dynamics.

Impact of Faun Pharma

While Zinzino reported robust growth, their subsidiary, Faun Pharma, noted a decline in external sales, which dipped to SEK 4.2 million from SEK 9.7 million. This decline could be a point of concern for the management, as they explore strategies to stabilize and grow this segment in the future.

Outlook Ahead

With such stellar performance in February 2025, Zinzino remains optimistic about the upcoming months. The management anticipates continued momentum, supported by strategic initiatives and innovative new product launches. Consumers' growing awareness of health and wellness products continues to play a crucial role, promising a bright future for Zinzino’s ambitions.

This impressive revenue growth emphasizes Zinzino's potential for clocking higher sales across diverse markets. The company's ongoing commitment to quality and customer satisfaction appears to resonate well within the marketplace, paving the way for further expansions and successful outcomes.

Contact Details

For further information, the CEO of Zinzino, Dag Bergheim Pettersen, is available for comments and can be contacted at +47 (0) 932 25 700. Visit their website at www.zinzino.com for updates and news releases.